Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.61 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.53 |
| ▸ | NECTIN4 | Q96NY8 | 3/20 | 0.49 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.48 |
| ▸ | TNFRSF9 | Q07011 | 4/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.46 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.45 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20013155 | 0.97 | CD274 (0.61) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL22199492 | 0.96 | CD274 (0.62) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL20013173 | 0.95 | CD274 (0.60) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL17760972 | 0.93 | CD274 (0.56) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL21908259 | 0.91 | CD274 (0.55) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL22199647 | 0.91 | CD274 (0.55) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL20013481 | 0.91 | CD274 (0.65) | CD274PDCD1NECTIN4CIB1EPHA2 | |
| SCHEMBL20013145 | 0.90 | CD274 (0.53) | CD274PDCD1NECTIN4CIB1TNFRSF9 | |
| SCHEMBL17810866 | 0.90 | CD274 (0.69) | CD274PDCD1NECTIN4CIB1EPHA2 | |
| SCHEMBL17815184 | 0.89 | CD274 (0.69) | CD274PDCD1CIB1EPHA2TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | CD274 36/4885PDCD1 79/4885NECTIN4 266/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | CD274 36/4885PDCD1 79/4885NECTIN4 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.